Tempest Therapeutics files prospectus for 2.427M share offering
Tempest Therapeutics filed a prospectus for the offering of 2.427M common shares on behalf of selling shareholders. The filing was submitted to the SEC. The shares are being offered by existing stakeholders.
*this image is generated using AI for illustrative purposes only.
Tempest Therapeutics has filed a prospectus with the SEC for the offering of 2.427M common shares on behalf of selling shareholders. The filing outlines the details of the proposed sale, specifying that the shares are being offered by existing stakeholders rather than the company itself. This move allows selling shareholders to liquidate a portion of their holdings in the open market.
The prospectus provides regulatory documentation required for the transaction, ensuring compliance with securities laws. It does not indicate any new capital raise for Tempest Therapeutics, as the proceeds from the sale will go directly to the selling shareholders. The filing is a standard procedural step for such offerings.
Key Details of the Offering
| Detail | Information |
|---|---|
| Total Shares Offered | 2.427M |
| Share Type | Common Shares |
| Offeror | Selling Shareholders |
| Filing Entity | Tempest Therapeutics |
The document serves as the primary source of information for potential investors regarding the specific terms and conditions of the share sale. It includes risk factors and other disclosures mandated by the SEC to protect investors.
How will the increased float from this secondary offering impact Tempest Therapeutics' stock liquidity and volatility?
What does the decision of major stakeholders to liquidate holdings signal about their confidence in the company's near-term clinical pipeline?
Could this sale put downward pressure on the share price, and how might the company manage potential market perception issues?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
